The Michael J. Fox Foundation

The foundation uses a centralized portfolio review process led by internal scientific staff and external peer reviewers. Proposals are evaluated on scientific rationale, milestone feasibility, and strategic alignment against an internal therapeutic roadmap that spans genetic targets, biomarker development, and symptomatic treatments. Unlike traditional grantmakers, MJFF requires data-sharing agreements and active project management from its program officers, who often sit on steering committees for funded consortia.

Deborah W. Brooks, co-founder and CEO, oversees the executive team that approves major grant allocations. The scientific strategy is driven by the chief scientific officer and a network of external scientific advisors. The board of directors, which includes David Einhorn and Ryan Reynolds, provides governance oversight and fundraising leadership rather than day-to-day grant decisions.

Funding comes from a diversified mix of major gifts, grassroots events through the Team Fox community, corporate partnerships, and planned giving vehicles. Google co-founder Sergey Brin is the most prominent individual donor, having directed over $150 million to MJFF-affiliated research programs (per Forbes, 2020), motivated in part by his own LRRK2 genetic status. The foundation does not maintain a large endowment; it raises capital programmatically for specific initiatives.

No, MJFF is a 501(c)(3) nonprofit and does not take equity positions. However, it operates like a venture investor by providing milestone-based funding to companies developing Parkinson's therapeutics. These grants often de-risk early clinical programs, enabling portfolio companies like Denali Therapeutics and Voyager Therapeutics to attract subsequent venture capital or pharmaceutical partnerships.

MJFF runs its own multi-site clinical studies through consortia that it coordinates directly, including the Parkinson's Progression Markers Initiative, which has enrolled over 1,500 participants longitudinally. The foundation mandates open-access data sharing and standardized protocols across all funded trials, which reduces duplication and speeds biomarker validation in ways that individual corporate sponsors typically avoid due to competitive concerns.

Michael J. Fox is the founder and public face of the organization, not its sole funder. The foundation is a separately incorporated nonprofit that raises the vast majority of its capital from external donors. Fox's contribution is primarily in advocacy, visibility, and governance — he does not function as a single-family-office principal directing a personal fortune, though his name and story are central to the foundation's fundraising identity.

The largest allocation historically has gone to therapeutic development programs targeting disease-modifying treatments. This includes funding for genetic targets like LRRK2 and GBA, alpha-synuclein pathology research, and neuroprotective strategies. The foundation also invests heavily in biomarker validation and clinical trial infrastructure, which collectively aim to accelerate regulatory endpoints for Parkinson's therapies.